Study at a glance
How can vitamin D attaching to its receptor lead to a change in the body?
Active vitamin D can attach to its receptor, which works with other proteins to control gene activity. The cell’s genetic material must be accessible, gene activity must change and those changes must affect cell or tissue function.
Why is showing that vitamin D attaches to its receptor not enough?
Attaching shows that molecules can interact. It does not establish which genes will respond inside a cell or whether the response changes an organ’s function. Different experiments are needed to test those later steps.
What can restoring receptors in an animal show?
Restoring vitamin D receptors in selected tissues can reveal whether that restoration is enough to recover a function in the tested model. It does not by itself show that the same tissue is the only place the function can be supported, or establish a treatment benefit in people.
Read the full article below ↓Vitamin D receptor evidence becomes misleading when different levels of proof are treated as interchangeable. A crystal structure can show that VDR recognises a ligand; a DNA structure can show how receptor complexes recognise a response element; genomic studies can show where VDR occupies chromatin; transcriptional experiments can show whether gene expression changes; and tissue-specific knockout and rescue experiments can test whether VDR action is necessary or sufficient for a physiological response. The value of a bridge across these layers is to preserve the chain while preserving each layer’s inference ceiling.
Layer 1: ligand binding establishes molecular recognition
Structural work with the VDR ligand-binding domain shows a defined pocket for 1α,25-dihydroxyvitamin D3 and an agonist-compatible receptor conformation. Tocchini-Valentini’s comparison with 20-epi agonists shows that different ligands can adapt within that pocket while stabilising a similar active receptor state. Masuno’s LCA structures push the point further: a chemically different bile-acid scaffold can occupy the same pocket in an opposite orientation while retaining many of the interactions needed for activation.
This layer answers whether the receptor can recognise a chemical signal and adopt an activation-compatible state. It does not establish where VDR is expressed, which genomic sites are accessible or whether a tissue-level phenotype follows.
Layer 2: DNA recognition establishes regulatory competence
VDR’s DNA-binding domain performs a separate job. Shaffer and Gewirth resolved VDR DNA-binding-domain complexes on several direct-repeat response elements and showed that sequence changes alter affinity and complex stability. Dimerisation contacts also help determine receptor assembly, while RXR partnership is central to the major transcriptionally active VDR complex.
A structurally competent VDR/RXR: DNA complex therefore moves the inference from chemical recognition to regulatory competence. It still does not prove that the same response element is accessible in chromatin inside a particular cell.
Layer 3: chromatin determines which potential sites are actually available
Genome-wide VDR studies demonstrate why the next layer cannot be skipped. Ramagopalan identified 2,776 VDR-occupied genomic positions after ligand stimulation but only 229 significantly responsive genes in the same model. Occupancy is therefore not synonymous with transcription. Seuter later showed 8,979 ligand-sensitive chromatin-accessibility loci in THP-1 cells, with opening peaking around 24 hours and most sites closing again by 48 hours; CTCF occupied a material subset of those responsive regions.
Those findings place VDR inside a dynamic regulatory landscape. The receptor may be biochemically capable of recognising a DNA motif while the cellular chromatin state determines whether that motif is available at a given time.
Layer 4: regulatory networks determine how occupancy becomes a transcriptional programme
Integrated cistrome, open-chromatin and transcriptome analysis in monocytes adds a network layer. Warwick and colleagues identified primary VDR targets that themselves encode transcription factors and validated downstream roles for factors including CEBPA and ETS1. In the same system, VDR knockout abolished the ligand-induced genome-wide transcriptional response. That knockout result changes the evidential strength: it shows that the measured transcriptional programme required VDR, not merely that VDR binding and gene expression occurred together.
Carlberg and Campbell and Pike provide the wider mechanistic synthesis: VDR/RXR action is coordinated with co-regulators, enhancer architecture and cell-specific regulatory factors. The useful inference is not that VDR independently dictates every target, but that receptor activation is embedded within an existing regulatory system.
Layer 5: three-dimensional genome organisation can contribute to regulation
CTCF HiChIP extended the chromatin model into three dimensions. Warwick’s 2022 study found ligand-associated changes in more than 3,000 CTCF interactions, with VDR sites and vitamin-D-responsive genes enriched in differential loops. CRISPR interference at a VDR/CTCF loop anchor and deletion of selected loop anchors altered gene regulation, showing that at least some spatial contacts are functionally involved.
This is stronger than a flat co-location map, but it remains cellular evidence. A functional loop in THP-1 cells does not prove that the same loop architecture governs every tissue.
Receptor expression defines capacity, not the endpoint
Between genomic competence and tissue causality sits another distinction: how much VDR is present and how its expression is regulated. Lee and Meyer’s in-vivo synthesis shows that VDR abundance is itself tissue: and context-dependent, while Lee and colleagues’ BAC-transgene work demonstrates that appropriately regulated receptor expression can restore hormone-responsive gene expression in the relevant tissues of VDR-null mice. This layer matters because receptor abundance sets the capacity for signalling, but neither abundance nor correct expression alone proves which genomic sites will be occupied or which physiological function will depend on the receptor.
Layer 6: tissue-restricted rescue tests physiological sufficiency
The most downstream question is whether VDR action in a defined tissue is sufficient or necessary for organism-level physiology. Tissue-restricted mouse experiments provide that causal step. Xue and Fleet restored VDR in intestine on a VDR-null background and normalised duodenal vitamin-D-regulated calcium absorption, calcium-transport genes, growth, serum calcium and parathyroid hormone. The rescue also revealed residual renal and bone consequences, showing that restoring one tissue can correct one causal bottleneck without making every VDR function intestinal.
Dhawan and colleagues narrowed the experiment further by expressing human VDR only in ileum, cecum and colon of VDR-null mice. Two lines with adequate distal-intestinal VDR expression prevented growth arrest, hypocalcaemia and elevated PTH and rescued major bone abnormalities despite no VDR expression in duodenum, jejunum, kidney or other tissues. A third line with much lower distal VDR expression showed only partial rescue. This is causal tissue evidence: it tests physiological sufficiency rather than inferring function from receptor detection.
Lee and colleagues used mouse and human VDR BAC transgenes to restore regulated VDR expression across appropriate tissues in VDR-null mice and rescued broad mineral, skeletal, endocrine and skin phenotypes. Together, these experiments show why tissue physiology requires perturbation evidence that structure and genomic occupancy cannot supply.
The chain is cumulative, but the layers must not be collapsed
The evidence can be read as a sequence: ligand recognition establishes receptor activation potential; DNA recognition establishes regulatory competence; chromatin accessibility and three-dimensional organisation constrain genomic access; transcription-factor networks shape the expression response; and tissue-specific perturbation establishes physiological causality. Evidence becomes stronger downstream only when the relevant intermediate steps have actually been tested.
The reverse is equally important. A physiological rescue does not explain every molecular interaction that preceded it, while a receptor structure cannot forecast the full organismal phenotype. Keeping those inference ceilings intact prevents common errors such as equating receptor presence with response, occupancy with gene regulation, or gene regulation with tissue necessity.
Start with Vitamin D Receptors. The structural layer is developed in Vitamin D Receptor Structure and Ligand Recognition; the canonical transcriptional layer in Cellular Signalling Mechanisms of Active Vitamin D; the chromatin layer in VDR Cistrome, Chromatin and 3D Genome Organisation; and the tissue-causal layer in Tissue-Specific VDR Physiology: Knockout and Rescue Evidence.
Evidence used to connect these layers
- Tocchini-Valentini et al. 2001 · ligand-bound VDR structure.
- Shaffer & Gewirth 2002 · response-element recognition and dimerisation.
- Pike et al. 2017 · genomic VDR synthesis.
- Lee et al. 2014 · BAC transgene expression and VDR-null rescue.
- Lee & Meyer 2018 · VDR expression/regulation in vivo.
- Carlberg & Campbell 2013 · integrated VDR transcriptional mechanism.
- Ramagopalan et al. 2010 · genome-wide VDR occupancy.
- Seuter et al. 2016 · dynamic accessibility and CTCF.
- Warwick et al. 2021 · VDR dependency and regulatory hierarchy.
- Warwick et al. 2022 · 3D chromatin and CRISPR perturbation.
- Xue & Fleet 2009 · intestine-specific VDR rescue.
- Dhawan et al. 2017 · distal-intestine-restricted VDR rescue.
- Masuno et al. 2013 · alternative-ligand structural recognition.
Related reading
1α,25(OH)2-3-Epi-Vitamin D3, a Natural Physiological Metabolite of Vitamin D3: Its Synthesis, Biological Activity and Crystal Structure with Its Receptor
In vivo action of 1α,25(OH)2-3-epi-D3 is tissue-specific and exhibits lowest calcemic effect compared to that induced by 1α,25(OH)2D3.
Original paper ↗Read more →Differential gene regulation by a synthetic vitamin D receptor ligand and active vitamin D in human cells
Vitamin D (VD) exerts a wide variety of biological functions including calcemic activity.
Original paper ↗Read more →The psychiatric risk gene BRD1 modulates mitochondrial bioenergetics by transcriptional regulation
Bromodomain containing 1 (BRD1) encodes an epigenetic regulator that controls the expression of genetic networks linked to mental illness.
Original paper ↗Read more →Vitamin D Receptor Gene Expression in Adipose Tissue of Obese Individuals is Regulated by miRNA and Correlates with the Pro-Inflammatory Cytokine Level
Results: VDR mRNA levels were higher, while CYP27B1 levels were lower in adipose tissues of obese patients than in those of normal-weight controls (VAT: P = 0.04, SAT: P < 0.0001 and VAT: P = 0.004, SAT: P = 0.016, respectively).
Original paper ↗Read more →Tissue-Specific VDR Pathway Gene Expression Is Not Associated with Circulating 25OHD in Adolescents with Severe Obesity
This study examined the expression patterns of VDR-target genes across metabolically diverse tissues and compared these molecular measures with circulating serum 25-hydroxyvitamin D (25OHD), the current clinical marker of vitamin D status.
Original paper ↗Read more →Investigating the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors
This study aimed to investigate the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors.
Original paper ↗Read more →Investigating the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors
This study aimed to investigate the level of vitamin D receptor gene expression in two tumoral and healthy breast tissues in breast cancer patients and its association with prognostic factors.
Original paper ↗Read more →Plasma 25-Hydroxyvitamin D Levels and VDR Gene Expression in Peripheral Blood Mononuclear Cells of Leukemia Patients and Healthy Subjects in Central Kazakhstan
A similar difference was observed in both younger (60 years old) participants, though there was no association between 25(OH)D concentration and age within the patient group.
Original paper ↗Read more →The impact of vitamin D supplementation on VDR gene expression and body composition in monozygotic twins: randomized controlled trial
The objective of this randomised controlled study is to examine the effect of vitamin D supplementation on body composition and the expression of the vitamin D receptor (VDR) mRNA.
Original paper ↗Read more →VDR, SOD-2, and CYP24A1 Gene Expression in Different Genotypes of BsmI SNP of the Vitamin D Receptor Gene in Individuals with Hypovitaminosis
Objective: To evaluate the effect of the genotypes of BsmI single nucleotide polymorphism (SNP) of the VDR gene on VDR, SOD2, and CYP24A1 gene expression in individuals with low serum vitamin D levels.
Original paper ↗Read more →Diverse Regulation of Vitamin D Receptor Gene Expression by 1,25-Dihydroxyvitamin D and ATRA in Murine and Human Blood Cells at Early Stages of Their Differentiation
Vitamin D receptor (VDR) is present in multiple blood cells, and the hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25D) is essential for the proper functioning of the immune system.
Original paper ↗Read more →Evolution of Vitamin D Status and Vitamin D Receptor Gene Expression Among Professional Handball Athletes During a Competitive Period. Relationship with Body Composition, Calcium, Magnesium and Phosphorous
Introduction: A generalized risk of vitamin D deficiency exists worldwide affecting also professional and elite athletes.
Original paper ↗Read more →Osteoblast-Specific Transcription Factor Osterix Increases Vitamin D Receptor Gene Expression in Osteoblasts
For example, calvaria obtained from Osx-null embryos displayed dramatic reductions in VDR expression compared to wild-type calvaria.
Original paper ↗Read more →The association between body mass index elevation and differentiation in vitamin D receptor gene expression, genetic polymorphism, and oxidative stress in adult Egyptian individuals
Vitamin D plays a central role in maintaining calcium, phosphorus, and bone homeostasis in close interaction with the parathyroid hormone.
Original paper ↗Read more →Vitamin D Receptor Gene Expression and Function in a South African Population: Ethnicity, Vitamin D and FokI
Polymorphisms of the vitamin D receptor gene (VDR) have been associated inconsistently with various diseases, across populations of diverse origin.
Original paper ↗Read more →Vitamin D Receptor Polymorphisms and Their Association with Nrf2-Dependent Gene Expression in Oxidative Stress Resilience in Cognitively Healthy Aging
For TaqI, homozygous carriers of the protective C allele exhibited greater PBMC viability (p < 0.0465) and higher Nrf2 (p = 0.0324), HMOX1 (p = 0.0206), and GST (p = 0.0029) expression compared with carriers of the risk T allele (TC or TT).
Original paper ↗Read more →Relationship between Structure and Conformational Change of the Vitamin D Receptor Ligand Binding Domain in 1α,25-Dihydroxyvitamin D3 Signaling
Vitamin D Receptor (VDR) belongs to the nuclear receptor (NR) superfamily.
Original paper ↗Read more →Lithocholic Acid and Alternative VDR Ligands: Evidence Synthesis
Evidence synthesis of lithocholic acid and related alternative VDR ligands, including binding, receptor structure and ileal responses.
Read more →Without 1α-hydroxylation, the gene expression profile of 25(OH)D3 treatment overlaps deeply with that of 1,25(OH)2D3 in prostate cancer cells
Recently, the antiproliferative action of 1,25(OH)2D3 (1,25D3), an active metabolite of vitamin D3, in the management of prostate cancer has been argued rigorously.
Original paper ↗Read more →Tissue-Specific VDR Physiology: Knockout and Rescue Evidence
Causal knockout and rescue evidence showing how tissue-specific VDR expression contributes to calcium, bone and whole-body physiology.
Read more →Functional Consequences of Tissue-Specific Vitamin D Signalling: Full Study
In-depth analysis of functional outcomes associated with tissue-specific vitamin D signalling.
Read more →Original sources
Tocchini-Valentini et al. 2001
Tocchini-Valentini et al.
Publication details
Tocchini-Valentini et al. 2001 · ligand-bound VDR structure.
Shaffer & Gewirth 2002
Shaffer & Gewirth 2002 · response-element recognition and dimerisation.
Publication details
Shaffer & Gewirth 2002 · response-element recognition and dimerisation.
Pike et al. 2017
Pike et al. 2017 · genomic VDR synthesis.
Publication details
Pike et al. 2017 · genomic VDR synthesis.
Lee et al. 2014
Lee et al. 2014 · BAC transgene expression and VDR-null rescue.
Publication details
Lee et al. 2014 · BAC transgene expression and VDR-null rescue.
Lee & Meyer 2018
Lee & Meyer 2018 · VDR expression/regulation in vivo.
Publication details
Lee & Meyer 2018 · VDR expression/regulation in vivo.
Carlberg & Campbell 2013
Carlberg & Campbell 2013 · integrated VDR transcriptional mechanism.
Publication details
Carlberg & Campbell 2013 · integrated VDR transcriptional mechanism.
Ramagopalan et al. 2010
Ramagopalan et al. 2010 · genome-wide VDR occupancy.
Publication details
Ramagopalan et al. 2010 · genome-wide VDR occupancy.
Seuter et al. 2016
Seuter et al. 2016 · dynamic accessibility and CTCF.
Publication details
Seuter et al. 2016 · dynamic accessibility and CTCF.
A hierarchical regulatory network analysis of the vitamin D induced transcriptome reveals novel regulators and complete VDR dependency in monocytes
The transcription factor vitamin D receptor (VDR) is the high affinity nuclear target of the biologically active form of vitamin D3 (1,25(OH)2D3).
Publication details
Warwick et al. 2021 · VDR dependency and regulatory hierarchy.
Warwick et al. 2022
Warwick et al. 2022 · 3D chromatin and CRISPR perturbation.
Publication details
Warwick et al. 2022 · 3D chromatin and CRISPR perturbation.
Xue & Fleet 2009
Xue & Fleet 2009 · intestine-specific VDR rescue.
Publication details
Xue & Fleet 2009 · intestine-specific VDR rescue.
Dhawan et al. 2017
Dhawan et al. 2017 · distal-intestine-restricted VDR rescue.
Publication details
Dhawan et al. 2017 · distal-intestine-restricted VDR rescue.
Masuno et al. 2013
Masuno et al. 2013 · alternative-ligand structural recognition.
Publication details
Masuno et al. 2013 · alternative-ligand structural recognition.